JP2003201383A - Material and module for hemocatharsis using the same - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a material which can suppress activation of blood platelets while retaining an insolubilized condition of a polyvinyl pyrroridone and its production method. <P>SOLUTION: The material comprises forming a separation membrane composed of polyvinyl pyrroridone having a variable amount of ≥300 and a soluble amount of ≤15 wt.%. <P>COPYRIGHT: (C)2003,JPO

Description

Detailed Description of the Invention

[0001]

TECHNICAL FIELD The present invention relates to a material, and is particularly preferably used for a polysulfone-based separation membrane having antiplatelet adhesion.

[0002]

2. Description of the Related Art Currently, various polymer materials are used in the medical field, but artificial blood vessels, catheters, blood bags,
In a device such as an artificial kidney that is in direct contact with blood, the adhesion of blood components such as plasma proteins and platelets, and the formation of thrombus resulting therefrom are major problems. Particularly in separation membranes used for blood purification, activation of platelets can cause residual blood. Therefore, in order to ameliorate these problems, a blood compatible material with less platelet adhesion is desired.

Conventionally, as materials for blood purification materials, polymers such as cellulose, cellulose acetate, cellulose triacetate, polyolefin, polyimide, polycarbonate, polyarylate, polyester, polyacrylonitrile, polymethylmethacrylate, polyamide, and polysulfone-based polymer are used. Compounds have been used.
Among them, polysulfone-based polymers have excellent heat resistance and are used for various separation membranes and films including dialysis membranes. Particularly when used as a blood purification material, a hydrophilic polymer such as polyvinylpyrrolidone is blended and used to impart blood compatibility.

The polyvinylpyrrolidone blended in the separation membrane is usually insolubilized by irradiation to prevent elution from the membrane. However, it is known that when the insolubilization treatment is performed, platelets are activated when blood comes into contact with the membrane surface, and residual blood increases (Patent Document 1).
Etc.).

[0005]

[Patent Document 1] Japanese Patent Laid-Open No. 9-323031

[0006]

DISCLOSURE OF THE INVENTION The object of the present invention is to improve the above-mentioned drawbacks of the prior art, and in particular, to a material which suppresses the activation of platelets while insolubilizing polyvinylpyrrolidone and blood compatibility using the same. To provide the material.

[0007]

In order to solve the above problems, the present invention has the following constitution.

That is, the present invention is a material comprising polyvinylpyrrolidone, characterized in that the polyvinylpyrrolidone has a mobility of 300 or more and a solubility of 15% by weight or less.

The present invention also relates to a module containing this material.

Further, in the method for producing the material of the present invention, a system in which a polysulfone-based polymer is mixed with a solvent in which polyvinylpyrrolidone is mixed and dissolved, and an additive for insoluble or swelling the polysulfone-based polymer is added is used as a stock solution for film formation. It is a method for producing a material characterized by being used.

[0011]

BEST MODE FOR CARRYING OUT THE INVENTION The weight average molecular weight of polyvinylpyrrolidone used in the present invention is not particularly limited, but it is preferably 2000 to 2,000,000, more preferably 10,000 to 1500000. From the viewpoint of easy availability, the weight average molecular weight of 1
Those of 100,000, 45,000, 29,000, 9000 and 2900 are preferably used. The weight average molecular weight of polyvinylpyrrolidone described here is the molecular weight at the stage of raw material used for the material. In the produced material, the molecular weight of polyvinylpyrrolidone is larger than that at the raw material stage when means such as radiation crosslinking is used.

Examples of products of polyvinylpyrrolidone include
"Kolidon" 12 PF, 17 PF, 25, 3
0, 90 (manufactured by BASF), "Rubiskor" K 1
7, K30, K80, K90 (manufactured by BASF), "Plasdon" K-29 / 32, K-25, K-90, K-90D, K90-M (ISP) Made)
And the like, such as polyvinylpyrrolidone.

The polyvinylpyrrolidone used in the present invention is preferably a homopolymer, but may be a copolymer with another monomer within a range not impairing the effects of the present invention. Here, the amount of the other copolymerizable monomer is not particularly limited, but is preferably 80% by weight or less.

Examples of commercial products of polyvinylpyrrolidone copolymer are "Kolidone" VA 64 (manufactured by BASF),
"RUVISCOL" VA 64 (manufactured by BASF), "RUBITEC" VPI55 K18P, VPI55 K72
W, same Quat 73W, same VPMA 91W, same VPC
55 K65W (manufactured by BASF), "Plasdon" S-
Examples thereof include polyvinylpyrrolidone copolymers such as 630 (manufactured by ISP).

The material of the present invention contains polyvinylpyrrolidone. In order to stably hold polyvinylpyrrolidone as a material form and prevent it from being eluted in large amounts, deformed or disintegrated, polyvinylpyrrolidone is supported. It is preferable to combine and use the material which becomes a body.
The method of forming and combining the polyvinylpyrrolidone and the material to be the support is not particularly limited, and the material to be the support and polyvinylpyrrolidone may be laminated, but it is preferable that they are mixed or compatible with each other. preferable.

The material for the support is not particularly limited, but an organic polymer is preferable. A polysulfone-based polymer is preferably used as the organic polymer.

The amount of polyvinylpyrrolidone contained in the material of the present invention is not particularly limited, but in many cases, the support is required to have a certain level of strength.
50% by weight or more and more preferably 1% by weight or more 1
It is preferably 0% by weight or less. This content can be confirmed by known methods such as elemental analysis and NMR (nuclear magnetic resonance analysis) alone or in combination.

The polysulfone-based polymer preferably used as a raw material of the material in the present invention has an aromatic ring, a sulfonyl group and an ether group in the main chain. For example, polysulfone represented by the following chemical formulas 1 and 2 is suitable. Although used, the present invention is not limited thereto. Here, n in the formula is an integer indicating the degree of polymerization, and preferably 5
It is an integer in the range of 0-80.

[0019]

[Chemical 1]

[0020]

[Chemical 2]

Examples of commercial products of polysulfone include "Udel" P-1700, P-3500 (manufactured by Teijin Amoco), "Ultrazone" S3010, and S6010.
(Manufactured by BASF), "Victorex" (Sumitomo Chemical),
"Radel" A-200A, A-300, "Radel" R-5000, R-5800 (manufactured by Teijin Amoco), "Ultrazone" E (manufactured by BASF), "Sumika Excel" (Sumitomo Chemical Co., Ltd.) Polysulfone, etc.).

The polysulfone used in the present invention is preferably a polymer consisting only of the repeating unit represented by the above chemical formula 1 and / or chemical formula 2, but is co-polymerized with other monomers within the range not impairing the effect of the present invention. It may be polymerized. The amount of the other copolymerizable monomer added is not particularly limited, but is preferably 10% by weight or less.

The material of the present invention may be mixed with the above-mentioned polyvinylpyrrolidone, a polymer other than the material to be the support, additives, etc. within a range that does not impair the effects of the present invention. The amount of addition of polyvinylpyrrolidone and the material other than the support material is not particularly limited, but is preferably 10% by weight or less.

The form of the material of the present invention is not particularly limited, and for example, it may be used in the form of a tube, beads, knitted fabric, non-woven fabric, cut fiber, flat membrane, hollow fiber membrane or the like. Further, the material may be dissolved in a solvent and molded into a specific shape, or may be coated. However, in the case of treatment efficiency, that is, when it is used for blood treatment, etc., a hollow fiber membrane is preferable in consideration of securing a surface area in contact with blood.

Further, the material of the present invention is preferably used as a separation membrane. In that case, the film thickness is 10 to 80 μ.
m is preferable and 20-50 micrometers is more preferable. Regarding the average pore size of the membrane, the 1% albumin permeability is 0.5.
% Or more is preferable, and 1% or more is more preferable. In the case of a hollow fiber membrane, the inner diameter of the hollow fiber is 100-300μ
m is preferable, and 150 to 200 μm is more preferable.

When the hollow fiber membrane is used, a conventionally known method can be used as a method for producing the hollow fiber membrane. The following method is a preferable method when polysulfone is used together with polyvinylpyrrolidone.

That is, a separation membrane characterized by using a system in which a polysulfone-based polymer and polyvinylpyrrolidone are mixed and dissolved with a solvent and an additive for insoluble or swelling the polysulfone-based polymer is added as a stock solution for membrane formation. Is a manufacturing method.

The weight ratio of the polysulfone polymer to polyvinylpyrrolidone is preferably 20: 1 to 1: 5, more preferably 5: 1 to 1: 1.

Further, as a good solvent for mixing and dissolving the polysulfone polymer and polyvinylpyrrolidone,
N, N-dimethylacetamide, dimethylsulfoxide, dimethylformamide, N-methylpyrrolidone, dioxane and the like are preferably used. The concentration of the polysulfone-based polymer is preferably 10 to 30% by weight, and 15 to 15% by weight is preferable.
25% by weight is more preferred.

As the additive for insolubilizing or swelling the polysulfone-based polymer, for example, water, methanol, ethanol, isopropanol, hexanol, 1,4-butanediol and the like can be mentioned. Considering the production cost, water is particularly preferably used. It When water is used, the polysulfone-based polymer has a high solidification property, and therefore the amount of water added is preferably 7% by weight or less, particularly preferably 1 to 5% by weight.
When an additive having a small solidification property is used, the addition amount may be large, and a suitable amount can be selected as appropriate.

The method for forming a film using the above-mentioned stock solution for film formation is not particularly limited, and a known method can be used. For example, it is possible to use a method in which an injection liquid is caused to flow inside when the stock solution for film formation is discharged from the double annular die, the dry type part is caused to travel, and then the solution is guided to a coagulation bath. At this time, since the humidity of the dry part has an effect, by supplying water from the outer surface of the membrane while running in the dry part, the phase separation behavior near the outer surface is accelerated, the pore size is expanded, and as a result, during dialysis. It is also possible to reduce the transmission / diffusion resistance. However, if the relative humidity is too high, the coagulation of the undiluted solution on the outer surface becomes predominant, and the pore size becomes smaller, and as a result, the permeation / diffusion resistance of the separation membrane tends to increase. Therefore, the relative humidity of the dry section is 60 to 9
0% is preferred. Further, as the composition of the injecting liquid, it is preferable to use one having a composition based on the solvent used for the stock solution for film formation, from the viewpoint of process suitability. Here, the concentration of the injection liquid is preferably 45 to 80% by weight, and more preferably 60 to 75% by weight, when dimethylacetamide is used.

In the present invention, the polyvinylpyrrolidone in the material is insolubilized. As a method for insolubilizing the polyvinylpyrrolidone, it is preferable to crosslink the polyvinylpyrrolidone contained in the material using radiation.

As the radiation treatment, it is preferable to irradiate the material with a wet γ-ray or electron beam. The wet state here means a state in which the material is not dried. Although the degree is not particularly limited, it is usually preferable that the material contains 1% by weight or more of water based on the weight of the material. Alternatively, the material may be immersed in an aqueous solution.

The absorbed dose of radiation is 10 to 50 in a wet state.
About kGy is preferable, and when irradiation is performed at a dose exceeding 20 kGy, it is possible to perform sterilization at the same time.
At this time, the absorbed dose can be measured by attaching a dose measurement label to the surface of the module.

The radiation-treated material can be preferably used as a separation membrane for blood purification. When used for blood purification, radiation treatment will also have a sterilizing effect at the same time, but if the sterilizing effect is insufficient, after irradiating radiation to insolubilize polyvinylpyrrolidone, steam sterilization, etc. Can be preferably used as.

When the absorbed dose of radiation is less than 10 kGy, polyvinylpyrrolidone is not easily insolubilized. Also 50k
When the irradiation amount is larger than that of Gy, the influence of deterioration on other materials such as the support polysulfone and the case may be large.

With polyvinylpyrrolidone insolubilized,
In order to increase the amount of mobility of polyvinylpyrrolidone, it can be obtained by subjecting a material containing polyvinylpyrrolidone to an aqueous solution containing a crosslinking inhibitor and performing radiation treatment in a wet state.

The cross-linking inhibitor is not particularly limited as long as it inhibits the cross-linking reaction. However, when it is used for blood purification, it is necessary to consider its safety, so that it has low toxicity. Those are preferably used. Among them, water-soluble vitamins, glycerin, alcohols such as ethanol, polyphenols, polyethyleneimine, polyethylene glycol, saccharides such as trehalose, inorganic salts such as sodium pyrosulfite, sodium hydrogencarbonate, oxygen, carbon dioxide, and the like are preferable. used. These crosslinking inhibitors may be used alone or in combination of two or more.

With respect to the concentration of the aqueous solution containing the crosslinking inhibitor, the preferred range varies depending on the crosslinking inhibitor contained, however, regardless of which crosslinking inhibitor is used, the polyvinylpyrrolidone has a mobility of 300 or more and a soluble amount. 15%
Must be below weight. For example, in the case of a glycerin aqueous solution, the glycerin concentration is 0.1% by weight or more and 10% by weight or less, in the case of an ethanol aqueous solution, 0.01% by weight or more and 5% by weight or less, and in the case of a polyethyleneimine aqueous solution, 0.01% by weight. The above content is preferably 5% by weight or less, but in the case of other crosslinking inhibitors, suitable concentration ranges can be selected.

Further, in order to reduce the solubility to 15% by weight or less, it is preferable not only to select a crosslinking inhibitor, but also to keep the dispersion state of polyvinylpyrrolidone before irradiation to an appropriate level. It is considered that the intertwined state is preferable. As the method, the composition of the materials, the mixing method, and the molding method may be selected so that the solubility is 15% by weight or less.
Increasing the polyvinylpyrrolidone content in the film-forming stock solution is a preferable method, and when the solubility is high, increasing the polyvinylpyrrolidone content promotes crosslinking, and reduces the solubility while keeping the amount of mobility high. You can For example, in a polysulfone / polyvinylpyrrolidone flat film obtained by sufficiently dissolving polysulfone and PVP in dimethylacetamide and then evaporating and drying dimethylacetamide, the polyvinylpyrrolidone content in the flat film is 1
When the content of polyvinylpyrrolidone was 66% by weight, the solubility was 15% by weight or less even when the film formation and radiation treatment conditions were the same except for the composition, when the content of polyvinylpyrrolidone was 66% by weight. Met. In the case of a hollow fiber membrane, for example, a film-forming solution consisting of 8% by weight or more of polyvinylpyrrolidone having a weight average molecular weight of more than 45,000, 18% by weight of polysulfone, 1% by weight of water, and the balance of dimethylacetamide is used. It is obtained by preparing a hollow fiber membrane and γ-irradiating it with an aqueous solution containing a glycerin concentration of 0.1 wt% to 10 wt%. In addition, in other cases, if the mobility is low, increase the amount of the crosslinking inhibitor,
When it is highly soluble, the target material can be obtained by appropriately selecting conditions such as increasing the content of polyvinylpyrrolidone.

The soluble amount of polyvinylpyrrolidone referred to herein is determined as follows. That is, the dried material is dissolved in N-methyl-2-pyrrolidone at a concentration of 2.5% by weight, and 1.7 times the amount of water is added to the solution to precipitate the raw material polymer. Soluble polyvinylpyrrolidone is included in the solution together with dispersed polysulfone microparticles. Polysulfone fine particles in the solution are removed by filtration with a non-aqueous filter (high performance liquid chromatography) for HPLC (manufactured by Tosoh, 2.5 μ diameter), and polyvinylpyrrolidone contained in the filtrate is quantified by HPLC (apparatus) :
Waters, GPC-244, column: TSKgel
GMPWXL x 2, solvent: water diameter, 0.1M ammonium chloride, 0.1N ammonia, pH 9.5, flow rate: 1.0
ml / min, temperature: 23 ° C). The soluble amount of polyvinylpyrrolidone contained per unit weight of the material was determined from the amount of polyvinylpyrrolidone contained in the filtrate, and it was divided by the amount of total polyvinylpyrrolidone contained per unit weight of the material determined from elemental analysis. The value is the soluble amount (%).

Further, the amount of mobility of polyvinylpyrrolidone referred to here is determined as follows.

That is, high resolution MAS (Magic Angle Spi)
nning, magic angle rotation method) NMR using solution probe
(Nuclear magnetic resonance analysis) is used. Specifically, the wet separation membrane washed with distilled water is immersed in a large excess of heavy water,
Replace with heavy water. At the same time, this operation also removes additives such as crosslinking inhibitors as much as possible. Then, replace the sample replaced with heavy water (the sample weight when dried is 5 mg) with a volume of 40 μm.
Packed in a dedicated cell of l while still wet, UNITY IN made by VARIAN
Perform 1H-NMR measurement with OVA600 type equipment (set a sufficiently long repetition time. About 10 μg of a heavy aqueous solution of TSP: sodium 3-trimethylsilylpropionate-2,2,3,3-d4 as an internal standard.
Addition, elimination of HDO peak by presaturation, MAS rotation speed 1600-1800Hz). In the obtained spectrum, the integrated value of the TSP peak (-0.2 to 0.2 ppm) is 100
The peak area derived from polyvinylpyrrolidone located at 2.9 to 4.2 ppm when 0.00 is determined. If it is disturbed by a peak derived from a crosslinking inhibitor (eg, polyethyleneimine) in the vicinity, find the peak area derived from polyvinylpyrrolidone located at 1.4 to 2.6 ppm, and obtain 1.4 to 2.6 ppm of a sample having various mobilities. And the actual area of the peak derived from polyvinylpyrrolidone located at 2.9 to 4.2 ppm can be determined from the calibration curve prepared from the peak area of 2.9 to 4.2 ppm.
This peak area corresponds to the amount of polyvinylpyrrolidone contained in the material. Therefore, the mobility of polyvinylpyrrolidone means a value obtained by dividing the peak area obtained as described above by the ratio (%) of all polyvinylpyrrolidone in the material obtained by elemental analysis.

The total amount of polyvinylpyrrolidone in the material can be determined by elemental analysis. That is, 0.2 to 0.5 mg of the dried material is added to a horizontal reactor (800 to
Nitrogen oxide produced by vaporization and oxidation at 950 ° C.) is measured by a chemiluminescence method (the apparatus uses TN-10 manufactured by Mitsubishi Chemical). For the quantification, the concentration can be automatically calculated in advance by a calibration curve prepared using a standard of a nitrogen-containing polymer.

Hereinafter, a method for testing platelet adhesion when the material of the present invention is a hollow fiber membrane will be described.

30 hollow fiber separation membranes are bundled, and both ends are fixed to a glass tube module case with an epoxy potting agent so as not to block the hollow parts of the hollow fibers to prepare a mini module. The mini-module has a diameter of about 7 mm and a length of about 10 cm. The blood inlet and dialysate outlet of the mini-module are connected by a silicone tube, 100 ml of distilled water is flown from the blood outlet at a flow rate of 10 ml / min, the hollow fiber and the inside of the module are washed, and then physiological saline is filled into the dialysate. Cap the entrance and exit. Next, the hollow fiber side was primed with physiological saline for 2 hours at a flow rate of 0.59 ml / min, and then 3.2% trisodium citrate dihydrate aqueous solution and rabbit fresh blood were mixed at 1: 9 (volume ratio). 7 ml of blood mixed in 1) is perfused for 1 hour at a flow rate of 0.59 ml / min. After that, wash with physiological saline with a 10 ml syringe, and 3%
The hollow fiber side and the dialysate side are filled with an aqueous solution of glutaraldehyde and left overnight to fix glutaraldehyde. Then, glutaraldehyde was washed with distilled water, the hollow fiber membrane was cut out from the mini module and dried. The inner surface of this hollow fiber membrane was observed with a scanning electron microscope to find that 1.1
The number of attached platelets in the area of 2 × 10 ³ μm ² was counted. The smaller the number of adhered platelets, the better the separation membrane. If it is not in the form of a hollow fiber membrane, the material may be immersed in blood to observe the adhered state, and if it is in the form of a flat plate, a flat plate may be placed at the bottom of the cylindrical tube, and blood may be added, etc. .

The material of the present invention can be suitably used as a transparent resin, a contact lens, an intraocular lens and other medical hydrogel materials, a hemodialysis membrane, a blood purification material such as an artificial kidney.

[0048]

EXAMPLES In the NMR measurement in the examples, the separation membrane was refrigerated and immersed in heavy water of 1000 times the weight of the membrane for 12 hours. The measurement was performed with a 45 ° pulse at a repetition time of 10 seconds.

(Example 1) 18 parts of polysulfone ("Udel" P-3500 manufactured by Teijin Amoco), 9 parts of polyvinylpyrrolidone ("Kolidone" 30 manufactured by BASF), 72 parts of N, N-dimethylacetamide, and 1 part of water In addition to
It was heated and dissolved at 90 ° C. for 14 hours. This film-forming stock solution has an outer diameter of 0.
A solution consisting of 58 parts of dimethylacetamide and 42 parts of water was discharged as a core liquid by discharging from an orifice type double cylinder type mouthpiece of 3 mm and an inner diameter of 0.2 mm, and after passing through a dry length of 350 mm, a coagulation bath of 100% water was prepared. A hollow fiber membrane was obtained.
The hollow fiber obtained had an inner diameter of 200 μm and a film thickness of 40 μm. The obtained hollow fiber membrane was irradiated with γ rays in an aqueous solution containing 1% by weight of glycerin. The absorbed dose of γ rays was 28 kGy. Table 1 shows the amount of mobility, the amount of solubility, and the number of attached platelets of polyvinylpyrrolidone in this hollow fiber membrane.

Example 2 The hollow fiber membrane obtained in the same manner as in Example 1 was irradiated with γ rays in an aqueous solution containing 0.5% by weight of glycerin. The absorbed dose of γ rays was 29 kGy.
Table 1 shows the amount of mobility, the amount of solubility, and the number of attached platelets of polyvinylpyrrolidone in this hollow fiber membrane.

Example 3 The hollow fiber membrane obtained in the same manner as in Example 1 was irradiated with γ rays in an aqueous solution containing 0.1% by weight of glycerin. The absorbed dose of γ rays was 29 kGy.
Table 1 shows the amount of mobility, the amount of solubility, and the number of attached platelets of polyvinylpyrrolidone in this hollow fiber membrane.

Example 4 The hollow fiber membrane obtained in the same manner as in Example 1 was irradiated with γ rays in an aqueous solution containing 1% by weight of polyethyleneimine (Wako Pure Chemical Industries, molecular weight 70,000). The absorbed dose of γ rays was 29 kGy. Table 1 shows the amount of mobility, the amount of solubility, and the number of attached platelets of polyvinylpyrrolidone in this hollow fiber membrane. The amount of mobility is 2.9-
Since the peak derived from polyvinylpyrrolidone located at 4.2 ppm was obstructed by the peak derived from polyethyleneimine, the peak area derived from polyvinylpyrrolidone located at 1.4 to 2.6 ppm was determined to be 1.4 to 2.6 pp.
The area of the peak derived from polyvinylpyrrolidone located at 2.9 to 4.2 ppm was determined from the calibration curve prepared from m and the peak area of 2.9 to 4.2 ppm.

(Comparative Example 1) The hollow fiber membrane obtained in the same manner as in Example 1 was irradiated with γ-rays in water. γ-ray absorbed dose is 2
It was 9 kGy. Table 1 shows the amount of mobility, the amount of solubility, and the number of attached platelets of polyvinylpyrrolidone in this hollow fiber membrane.

(Comparative Example 2) The hollow fiber membrane obtained in the same manner as in Example 1 was irradiated with γ rays while being wet with an aqueous solution containing 80% by weight of glycerin. γ-ray absorbed dose is 29 kG
It was y. Table 1 shows the amount of mobility, the amount of solubility, and the number of attached platelets of polyvinylpyrrolidone in this hollow fiber membrane.

Comparative Example 3 "A" manufactured by Asahi Medical Co., Ltd.
The hollow fiber was taken out from PS-150S "(lot number 008L8V-S, which was γ-ray sterilized). The mobility amount, the soluble amount, and the platelet adhesion number of polyvinylpyrrolidone in this hollow fiber membrane are shown in Table 1. .

(Comparative Example 4) Commercially available "PS-U" manufactured by Kawasumi Chemical Co., Ltd.
Hollow fibers were taken out from W "(lot number 082675, which had been subjected to high-pressure steam sterilization). The mobility amount, soluble amount, and platelet adhesion number of polyvinylpyrrolidone in this hollow fiber membrane are shown in Table 1.

(Comparative Example 5) In the same manner as in Example 1, γ-ray irradiation was carried out in an aqueous solution containing 0.05% by weight of glycerin.
The absorbed dose of γ rays was 27 kGy. Table 1 shows the amount of mobility, the amount of solubility, and the number of attached platelets of polyvinylpyrrolidone in this hollow fiber membrane.

[0058]

[Table 1]

From Table 1, the separation membranes of the examples were all excellent separation membranes having a small number of adhered platelets. On the other hand, a comparative example (Comparative Example 1, in which the mobility of polyvinylpyrrolidone is small)
In 5), the number of attached platelets was high. In addition, a comparative example in which the amount of soluble polyvinylpyrrolidone is too large (Comparative Example 2,
In 3 and 4), the number of attached platelets is small, but the elution of soluble polyvinylpyrrolidone is concerned.

[0060]

INDUSTRIAL APPLICABILITY The material of the present invention and the method for producing the same are extremely useful because they can be used for applications such as blood purifiers and can provide a material particularly excellent in antiplatelet adhesion.

─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. ⁷ Identification code FI theme code (reference) B01D 69/08 B01D 69/08 69/10 69/10 71/44 71/44 C08L 81/06 C08L 81 / 06 // D01F 6/76 D01F 6/76 D (72) Inventor ▲ Taka ▼ Mari Sakisaki 1111 Tehiro, Kamakura-shi, Kanagawa Toray Research Center Co., Ltd. F-term (reference) 4C077 AA05 BB01 KK01 KK13 KK30 LL02 LL05 PP15 4D006 GA02 HA01 JB01 MA01 MA09 MB11 MC57X NA21 NA42 NA45 PB09 PB46 PC41 PC47 4J002 BJ00W CN03X GB01 GD00 4L035 AA04 BB04 EE20 MF01

Claims (7)

[Claims] 1. A material containing polyvinylpyrrolidone, wherein the polyvinylpyrrolidone has a mobility of 300 or more,
A material having a soluble amount of 15% by weight or less. 2. The material according to claim 1, wherein the material comprises polyvinylpyrrolidone and its support, and the support is a polysulfone-based polymer. 3. The material according to claim 1, wherein the material is in the form of a separation membrane. 4. The material according to claim 1, wherein the material is a hollow fiber membrane. 5. The material according to claim 3, wherein the separation membrane is for blood purification. 6. A blood purification module comprising the separation membrane according to any one of claims 1 to 5 therein. 7. The blood purification module according to claim 6, which is used as an artificial kidney.